Novel series of 177Lu-labeled bombesin derivatives with amino acidic spacers for selective targeting of human PC-3 prostate tumor cells

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 3, 2011, Pages 310-323

  Pujatti, P Brunelli ^a   Santos, J S ^a   Couto, R M ^a   Melero, L T U H ^a   Suzuki, M F ^a   Soares, C R J ^a   Grallert, S R M ^a   Mengatti, J ^a   De Araujo E B ^a  

^a INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

Author keywords

Amino acidic spacer; Bombesin; Lutetium 177; Prostatic neoplasms

Indexed keywords

AMINO ACID; BOMBESIN DERIVATIVE; LUTETIUM 177;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SPECIFICITY; DRUG STABILITY; DRUG STORAGE; DRUG TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PROSTATE TUMOR; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TISSUE DISTRIBUTION;

EID: 79960983299     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Panigone S, Nunn AD. Lutetium-177-labeled gastrin releasing peptide receptor binding analogues: a novel approach to radionuclide therapy. Q J Nucl Med Mol Imaging 2006;50:310-21. (Pubitemid 46157612)
2. Engel JB, Schally AV, Dietl J, Rieger L, Hönig A. Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol Pharm 2007;4:652-8. (Pubitemid 350004264)
3. Weiner RE, Thakur ML. Radiolabeled peptides in diagnosis and therapy. Semin Nucl Med 2001;31:296-311.
4. Anastasi A, Erspamer V, Bucci M. Isolation and structure of bombesin and alytesin, two analogous active peptides from the skin of the European amphibians Bombina and Alytes. Experientia 1971;26:166-7.
5. Varvarigou AD, Bouziotis P, Zikos Ch, Scopinaro F, de Vicentis G. Gastrin-releasing peptide (GRP) analogues for cancer imaging. Cancer Biother Radiopharm 2004;19:219-29. (Pubitemid 38685120)
6. Maina T, Nock BA, Zhang H, Nikolopoulou A, Waser W, Reubi JC et al. Species differences of bombesin analog interactions with GRP-R define the choice of animal models in the development of GRP-R-targeting drugs. J Nucl Med 2005;46:823-30.
7. Patel O, Shulkes A, Baldwin GS. Gastrin-releasing peptide and cancer. Biochim Biophys Acta 2006;1766:23-41.
8. 177Lu]Lu-AMBA, a systemic radiotherapeutic agent for Gastrin Releasing Peptide receptor positive tumors. Appl Radiat Isot 2008;66:497-505.
9. 177Lu-labeled GRP-R agonist for systemic radiotherapy in human tissues. Clin Exp Metastasis 2009;26:105-19.
10. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999;59:1152-9. (Pubitemid 29135980)
11. Zhang H, Schuhmacher J, Waser B, Wild D, Eisenhut M, Reubi JC et al. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours. Eur J Nucl Med Mol Imaging 2007;34:1198-208. (Pubitemid 47296770)
12. 177Lu of specific activity and purity suitable for medical applications. J Radioanal Nucl Chem 2003;257:53-7. (Pubitemid 36876543)
13. Vértes A, Nagy S, Zoltan K. Handbook of Nuclear Chemistry, v.4. Kluwer Academic Publishers: Netherlands, 2003.
14. 0]octreotide in patients. Eur J Nucl Med 2001;28:1319-25. (Pubitemid 33815021)
15. Zhang H, Chen J, Waldherr C, Hinni K, Waser B, Reubi JC et al. Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors. Cancer Res 2004;64:6707-15. (Pubitemid 39302601)
16. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J Nucl Med 2006; 47:1144-52. (Pubitemid 47558898)
17. 64Cu-labeled bombesin analogue. Bioconjug Chem 2003;14:756-63. (Pubitemid 36875435)
18. 3. Cancer Res 2003;63:4082-8.
19. 99Tc]bombesin analogues with improved biodistribution for targeting gastrin releasing-peptide receptor positive tumors. Q J Nucl Med Mol Imaging 2007;51:42-50. (Pubitemid 46830276)
20. 2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. PNAS 2007;104:12462-67. (Pubitemid 47206160)
21. 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumors. Appl Radiat Isot 2009;67:227-33.
22. 99mTc-litorin and biodistribution in rats. Bioconjug Chem 2007;18:1516-20. (Pubitemid 47464059)
23. Murphy R, Tonantzitla I. Biexp. Puebla: México; 1991.
24. 4)-Bombesin(1-14). Bioconjug Chem 2007;18:724-30. (Pubitemid 47010791)
25. Haley TJ, Komesu N, Efrus M, Koste L, Uphan HC. Pharmacology and toxicology of lutetium chloride. J Pharm Sci 1964;53:1186-8.
26. th ed. Springer: United States of America; 2003.
27. 2. Nucl Med Biol 2002;29:423-30. (Pubitemid 34597114)
28. 177Lu-AMBA. Eur J Nucl Med Mol Imaging 2007;34:95-100. (Pubitemid 44885559)
29. 64Cu-labeled DOTA-Linker-Bombesin(7-14) analogues containing different amino acid linker moieties. Bioconjug Chem 2007;18:1110-7.
30. 2 structural paradigm in a prostate cancer model. Bioconjug Chem 2008;19:1803-12.
31. 3-DTMA bombesin conjugates having high affinity for the GRP receptor. Nucl Med Biol 2008;35:263-72.
32. 99mTc(I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumor. Nucl Med Biol 2002;29:553-60.